Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703971 · ClinicalTrials.gov registry record · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
A Phase 1 study of Small Cell Lung Cancer Extensive Stage, sponsored by Genprex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 17
- Study locations
NCT05703971 is a Phase 1 study of Small Cell Lung Cancer Extensive Stage that is actively recruiting participants, run by Genprex. The registered enrollment target is 62 participants, above the 37-participant average among 3 other Small Cell Lung Cancer Extensive Stage trials with a reported enrollment target (68% higher). The trial reports 17 study locations across 7 states.
The verdict
NCT05703971, a Phase 1 study of Small Cell Lung Cancer Extensive Stage, is actively recruiting participants, sponsored by Genprex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 17
- Study locations
Study Summary
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Conditions Studied
Interventions
- BIOLOGICAL quaratusugene ozeplasmid
- BIOLOGICAL atezolizumab
Study Locations (17)
Ohio
- Gabrail Cancer Center Research - Canton
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Fairfield
Oregon
- Willamette Valley Cancer Institute (Oregon) - Eugene
- Northwest Cancer Specialists, P.C. - Portland
- Providence Cancer Institute - Portland
- Northwest Cancer Specialists, P.C. - Portland
- Northwest Cancer Specialists, P.C. - Tigard
Texas
- Texas Oncology - DFW - Dallas
- Texas Oncology - Northeast Texas - Tyler
Colorado
- Rocky Mountain Cancer Centers, LLP - Lone Tree
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Washington
- Northwest Cancer Specialists, P.C. - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05703971
The ClinicalTrials.gov registry entry for NCT05703971 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 3 other Small Cell Lung Cancer Extensive Stage trials with a reported enrollment target (68% higher). The listed sponsor is Genprex, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Cancer Extensive Stage appearing as the primary indexed condition, and to 2 interventions - of which quaratusugene ozeplasmid is the first listed.
NCT05703971 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Ohio, Oregon, Texas.
Frequently Asked Questions
What is clinical trial NCT05703971 about?
NCT05703971 is a clinical study titled "Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients". This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase ...
What is the current status of trial NCT05703971?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2024-05-09. Estimated completion is 2027-08.
What conditions does trial NCT05703971 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer Extensive Stage.
What interventions are being tested in trial NCT05703971?
The interventions under investigation include: quaratusugene ozeplasmid (BIOLOGICAL), atezolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05703971?
This trial is sponsored by Genprex, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703971 being conducted?
This trial has 17 study locations across Colorado, Missouri, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer Extensive Stage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
-
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 1
-
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.